» Articles » PMID: 37463569

Critical Evaluation of Transcripts and Long Noncoding RNA Expression Levels in Prostate Cancer Following Radical Prostatectomy

Abstract

Introduction: The clinical course of prostate cancer (PCa) is highly variable, ranging from indolent behavior to rapid metastatic progression. The Gleason score is widely accepted as the primary histologic assessment tool with significant prognostic value. However, additional biomarkers are required to better stratify patients, particularly those at intermediate risk.

Methods: In this study, we analyzed the expression of 86 cancer hallmark genes in 171 patients with PCa who underwent radical prostatectomy and focused on the outcome of the 137 patients with postoperative R0-PSA0 status.

Results: Low expression of the IGF1 and SRD52A, and high expression of TIMP2, PLAUR, S100A2, and CANX genes were associated with biochemical recurrence (BR), defined as an increase of prostate-specific antigen above 0.2 ng/mL. Furthermore, the analysis of the expression of 462 noncoding RNAs (ncRNA) in a sub-cohort of 39 patients with Gleason score 7 tumors revealed that high levels of expression of the ncRNAs LINC00624, LINC00593, LINC00482, and cd27-AS1 were significantly associated with BR. Our findings provide further evidence for tumor-promoting roles of ncRNAs in PCa patients at intermediate risk. The strong correlation between expression of LINC00624 and KRT8 gene, encoding a well-known cell surface protein present in PCa, further supports a potential contribution of this ncRNA to PCa progression.

Conclusion: While larger and further studies are needed to define the role of these genes/ncRNA in PCa, our findings pave the way toward the identification of a subgroup of patients at intermediate risk who may benefit from adjuvant treatments and new therapeutic agents.

Citing Articles

Blockade of neutral sphingomyelinase 2 exerts antitumor effect on metastatic castration resistant prostate cancer cells and promotes tumor regression when combined with Enzalutamide.

Shams S, Dawud D, Michalak K, Makhlouf M, Moustafa A, Jazwinski S Am J Cancer Res. 2025; 14(12):5697-5716.

PMID: 39803655 PMC: 11711525. DOI: 10.62347/XXXA3182.


Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX.

Chang J, Yang Q, Liu X, Li W, Gao L Oncol Lett. 2024; 28(4):474.

PMID: 39161338 PMC: 11332572. DOI: 10.3892/ol.2024.14607.


Role of N‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review).

Pan J, Tong F, Ren N, Ren L, Yang Y, Gao F Oncol Rep. 2024; 51(6).

PMID: 38757383 PMC: 11110010. DOI: 10.3892/or.2024.8747.

References
1.
Sandhu S, Moore C, Chiong E, Beltran H, Bristow R, Williams S . Prostate cancer. Lancet. 2021; 398(10305):1075-1090. DOI: 10.1016/S0140-6736(21)00950-8. View

2.
Quagliata L, Quintavalle C, Lanzafame M, Matter M, Novello C, Di Tommaso L . High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models. Lab Invest. 2017; 98(1):95-105. DOI: 10.1038/labinvest.2017.107. View

3.
Urban P, Vuaroqueaux V, Labuhn M, Delorenzi M, Wirapati P, Wight E . Increased expression of urokinase-type plasminogen activator mRNA determines adverse prognosis in ErbB2-positive primary breast cancer. J Clin Oncol. 2006; 24(26):4245-53. DOI: 10.1200/JCO.2005.05.1912. View

4.
Cao Z, Chen X, Xu Y, Guo F, Ji J, Xu H . Differential Expression and Prognostic Value of Cytoplasmic and Nuclear Cyclin D1 in Prostate Cancer. Biomed Res Int. 2020; 2020:1692658. PMC: 7281841. DOI: 10.1155/2020/1692658. View

5.
Carter H, Albertsen P, Barry M, Etzioni R, Freedland S, Greene K . Early detection of prostate cancer: AUA Guideline. J Urol. 2013; 190(2):419-26. PMC: 4020420. DOI: 10.1016/j.juro.2013.04.119. View